|Year : 2022 | Volume
| Issue : 1 | Page : 1-4
Chordoid Meningioma. Case Report and Review of the Literature
M Prokopienko1, T Wierzba-Bobrowicz2, W Grajkowska2, T Stępień2, M Sobstyl2
1 Department of Neurosurgery, Institute of Psychiatry and Neurology, Sobieskiego, Warsaw, Poland
2 Department of Neuropathology, Institute of Psychiatry and Neurology, Sobieskiego, Warsaw, Poland
|Date of Submission||02-Dec-2020|
|Date of Acceptance||31-Oct-2021|
|Date of Web Publication||19-Jan-2022|
Dr. M Prokopienko
Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland, Sobieskiego 9 Street, 02-957 Warsaw
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Chordoid meningioma is an uncommon histopathological type of meningioma, frequently associated with Castleman's syndrome. Histologically, chordoid meningiomas are similar to chordomas. Because of their high proliferative index, they present aggressive biological behavior and high risk of postoperative recurrence. We report a case of chordoid meningioma in an adult patient without Castleman's syndrome manifestation. As its chordoid feature is related with a rapid recurrence after incomplete removal, meticulous histopathological examination is crucial for the adequate postoperative treatment plan.
Keywords: Castleman's disease, chordoid meningioma, mitotic index
|How to cite this article:|
Prokopienko M, Wierzba-Bobrowicz T, Grajkowska W, Stępień T, Sobstyl M. Chordoid Meningioma. Case Report and Review of the Literature. Niger J Clin Pract 2022;25:1-4
|How to cite this URL:|
Prokopienko M, Wierzba-Bobrowicz T, Grajkowska W, Stępień T, Sobstyl M. Chordoid Meningioma. Case Report and Review of the Literature. Niger J Clin Pract [serial online] 2022 [cited 2022 Dec 3];25:1-4. Available from: https://www.njcponline.com/text.asp?2022/25/1/1/335991
| Introduction|| |
Meningioma is the most common benign intracranial tumor, representing 13%–36% of all primary central nervous system neoplasms. Among meningiomas, 90% are benign., Starting from 2007, all meningiomas with cortical invasion became considered as grade II. This increased the rate of these meningiomas from 5% to 20%–35%. Among grade II group, besides atypical and clear cell meningiomas, the rare type tumors constitutes chordoid meningiomas (CMs). CMs represent approximately less than 1% of intracranial meningiomas.,, The term CM was initially presented by Kepes et al. who defined it as having a chordoma-like histological appearance with a clustering of tumor cells. We report a 71-year-old patient with CM in parasagittal region infiltrating the superior sagittal sinus and motor cortex of the left hemisphere.
| Case Report|| |
A 71-year-old nonsmoking right-handed woman, presented with 2 months history of left leg paresis gradual progression. The patient was able to walk with the crutches. No sensory deficit was found. Cranial magnetic resonance imaging (MRI) revealed a 3 × 4 × 4 cm mass in the left occipital region with superior sagittal sinus infiltration [Figure 1]a and [Figure 1]b.
|Figure 1: (a and b) MRI scans showing choroid meningioma in axial and sagittal plane before surgery. (c and d) – MRI scans showing tumor remnants in the superior sagittal sinus 1 month after surgery, before Gamma Knife therapy. (e and f) – MRI scans 6 months after surgery, recently after Gamma Knife therapy|
Click here to view
Two weeks after the initial presentation, she underwent left frontoparietal craniotomy. Considering the superior sagittal sinus infiltration by the tumor, advanced age of the patient, a subtotal tumor resection was undertaken. Small tumor remnants within the sinus cavity were coagulated thoroughly. The infiltration of the arachnoid by the tumor increased the cerebral cortex injury. Left lower-limb paresis progression was observed immediately after the procedure, and it subsequently regressed during the rehabilitation. The patient was able to walk with crutches 2 months after surgery. Repeat MRI carried out 1 month after surgery confirmed tumor remnants within the superior sagittal sinus cavity [Figure 1]c, [Figure 1]d. The patient was reviewed by oncologist and stereotactic radiotherapy (Cyberknife) was applied to irradiate the remnants of the tumor within the superior sagittal sinus. No tumor tissue progression was observed 6 months after surgery [Figure 1]e and [Figure 1]f.
The sample tissue from neurosurgical procedure was fixed in 10% buffered formalin and paraffin embedded. The specimens were stained with hematoxylin-eosin and mucicarmine methods. Immunohistochemical studies were performed with antibodies to epithelial membrane antigen (EMA) (1:200, Leica clone GP1,4), cytokeratin, CK (1:50, DACO clone AE1/AE3), glial fibrillary acid protein, GFAP (1:300, Bio-Rad, clone 1B4), and Ki-67 (1:75, Invitrogen, clone SP6). The sections were examined and photographed.
Neuropathological examination revealed that samples of the tumor were composed of cords of round, ovoid, and epithelial cells, embedded in a prominent myxoid background [Figure 2]a,[Figure 2]b, and [Figure 2]d. Sometimes, mild nuclear atypia was focally present. The conventional meningothelial or transitional morphology was visible in small fields [Figure 2]c. Immunohistochemical staining showed positive staining for epithelial membrane antigen (EMA) [Figure 2]e. The Ki-67 labeling index was about 8% [Figure 2]f. The tumor cells were negative for glial fibrillary acid protein (GFAP) and cytokeratin (CK). Based on these findings, a final diagnosis of CM (WHO GII) was made.
|Figure 2: Neuropathological features of choroid meningioma with hemorrhage. (a) Cords of tumor cells and trabeculae of round, ovoid, and epithelial cells. H&E. (b) The tumor cells were embeded in a prominent myxoid backround. H&E. (c) Typical meningothelial areas with hemorrhage. H&E. (d) Tumor cells embeded in mucinous stroma. Mucicarmine. (e) Cords of tumor cells with intense EMA immunoreactivity. (f) Ki-67 labeling index shows nuclear immunoreactivity|
Click here to view
The tumor removal was subtotal. As the patient age did not encourage us to conduct more aggressive surgical treatment, she was referred for a radiation therapy.
| Discussion|| |
CMs are very rare tumors, as they represent only 0.5% of all meningiomas. Less than 300 cases have been reported worldwide to date. Kepes et al., who first described these lesions, reported their association with Castleman's syndrome. Castleman's disease is a rare disorder that involves an overgrowth of cells in your body's lymph nodes described by Benjamin Castleman in 1956. The most common form of the disorder affects a single lymph node, usually in the chest or abdomen. Couce et al. concluded that the systemic disease associated with CMs was restricted to children. No manifestation of systemic disease in adults was noted in his material.
Histologically, CMs are similar to chordomas. They contain trabeculae, or cords of eosinophilic vacuolated cells in a myxoid matrix. High mitotic rate, increased cellularity, small cell change, sheet like growth, macro nucleoli, and focal necrosis are present., Loewenstern et al. noticed moreover, that the mitotic index is a direct indicator of cell proliferation and predictor of tumor behavior. Aghi et al. reported that prominent nucleoli were associated with higher risk of recurrence. In material of Lee et al. focal necrosis was related with six-fold risk of recurrence. Baltus et al. found, that detection of chromothripsis in CM can be related with considerable potential of recurrence after initial surgery. One of the most important regrowth patterns of the tumor is the high chordoid features percentage. It was first described by Couce et al. Chordoid features greater than 50% as a significant tumor regression marker was emphasized also in later reports.,,, In the study of Matyja et al. significant chordoid component was concerned not only with high tumor recurrence rate, but also with more aggressive biological behavior. Hasegawa et al. described relation with high mucoid quality of the tumor with its rapid spread and recurrence. In the differential diagnosis, correct identification of the vacuolated trabeculae of neoplastic cells in a myxoid background characteristic of CM is straightforward when accompanied by coexisting areas of typical meningioma.
As the extent of resection is the most important prognostic factor in case of CM treatment, gross total resection (GTR) should be the goal for the surgical management of primary CM. It remains the strongest predictor of long-term rates of tumor control.,,,,,,,,,,,,, As the recurrence remains high following subtotal resection, careful follow-up should be recommended in every case. The most illustrative reason for careful observation was presented by Couce et al. In his long-term follow-up, all patients after a subtotal resection experienced tumor recurrence, whereas only one out of the 29 patients after a GTRs recurred. Similar observations were noticed in the study by Zhu et al. Although most of authors recommend adjuvant radiotherapy for atypical meningiomas in the management of residual disease following subtotal resection,,, its efficacy remains unclear. In cases of incomplete resections, Liu et al. justified its application as a method of salvage treatment. Conversely, in cases of complete tumor resections, most of the authors found no significant progression free survival rates increase after radiotherapy.,,,,, Only few case studies advocated for the role of radiotherapy after GTR.,
The MIB-LI (cell proliferation marker) is a histological marker for proliferative capacity, correlated with high rates of tumor control. Higher MIB-LI has been noted to correlate with recurrent meningiomas in studies of some authors.,,, Others did not share this opinion, founding no correlation with outcomes.,,
Other factors concerned with unfavorable overall results were presented by Zhang et al. In this large retrospective analysis, male gender, larger tumor size, surgical history, and bone invasion were defined as risk factors associated with poor outcome.
| Conclusions|| |
CMs constitute a rare and diverse subtype of WHO grade II meningiomas. The review of the literature evidenced, that the most important factor leading to progression free survival is GTR. The role of adjuvant radiotherapy remains controversial. It should be indicated in patients with subtotal resection and high MIB-LI.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initial s will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Poulen G, Vignes J-R, Le Corre M, Loiseau H, Bauchet L. WHO grade II meningioma: Epidemiology, survival and contribution of postoperative radiotherapy in a multicenter cohort of 88 patients. Neurochirurgie 2020;66:73-9.
Champeaux Ch, Dunn L. World Health Organization grade II meningioma: A 10-year retrospective study for recurrence and prognostic factor assessment. World Neurosurg 2016;89:180-6.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al
. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114: 97-109.
Choy W, Ampie L, Lamano JB, Kesavabhotla K, Mao Q, Parsa AT, et al
. Predictors of recurrence in the management of chordoid meningioma. J Neurooncol 2016;126:107-16.
Couce ME, Aker FV, Scheithauer BW. Chordoid meningioma: a clinicopathologic study of 42 cases. The American journal of surgical pathology. 2000;24:899-905.
Epari S, Sharma MC, Sarkar C, Garg A, Gupta A, Mehta VS. Chordoid meningioma, an uncommon variant of meningioma: A clinicopathologic study of 12 cases. J Neurooncol 2006;78:263-9.
Kepes JJ, Chen WY, Connors MH, Vogel FS. “Chordoid” meningeal tumors in young individuals with peritumoral lymphoplasmacellular infiltrates causing systemic manifestations of the Castleman syndrome. A report of seven cases. Cancer 1988;62:391-406.
Castleman B, Iverson L, Menedez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9:822-30.
Hasegawa S, Yoshioka S, Urabe S, Kuratsu J. Rapidly enlarging chordoid meningioma with abundant mucin production. Neuropathology 2006;26:438-41.
Sangoi AR, Dulai MS, Beck AH, Brat DJ, Vogel H. Distinguishing chordoid meningiomas from their histologic mimics: An immunohistochemical evaluation. Am J Surg Pathol 2009;33:669-81.
Loewenstern J, Shuman W, Rytland JW, Kessler RA, Kohli KM, Umphlett M, et al
. Preoperative and histological predictors of recurrence and survival in atypical meningioma after initial gross total resection. World Neurosurg 2019;128:e148-56.
Aghi MK, Carter BS, Cosgrove GR, Ojeman RG, Amin-Hanjani S, Martuza R, et al
. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009;64:56-60; discussion 60.
Lee KD, DePowell JJ, Air LL, Dwivedi AK, Kendler A. Atypical meningiomas: Is postoperative radiotherapy indcated? Neurosurg Focus 2013;35:e15.
Baltus C, Toffoli S, London F, Delrée P, Gilliard C, Gustin T. Chromothripsis in an early recurrent chordoid meningioma. World Neurosurg 2019;130:380-5.
Di Ieva A, Laiq S, Nejad R, Schmitz EM, Fathalla H, Karamchandani J, et al
. Chordoid meningiomas: Incidence and clinicopathological features of a case series over 18 years. Neuropathology 2015;35:137-47. Epub 2014 Nov 6.
Lin JW, Ho JT, Lin YJ, Wu YT. Chordoid meningioma: A clinicopathologic study of 11 cases at a single institution. J Neurooncology 2010;100:465-73.
Mitsuhashi T, Ono S, Inohara T, Otomo T, Aoki A, Ueki Y. Chordoid meningioma--case report. Neurol Med Chir (Tokyo) 2006;46:37-40.
Donato G, Ferraro G, Signorelli F, Iofrida G, Lavano A, Amarosi A, et al
. Chordoid meningioma: Case report and literature review. Ultrastruct Pathol 2006;30:309-14.
Ewa Matyja E, Grajkowska W, Łazarczyk M, Marchel A, Czernicki T. Chordoid meningiomas of a different histopathological pattern. A report of two cases. Folia Neuropathol 2006;44:34-41.
Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol 2010;99:379-91.
Arima T, Natsume A, Hatano H, Nakahara N, Fujita M, Ishii D, et al
. Intraventricular chordoid meningioma presenting with Castleman disease due to overproduction of interleukin-6. Case report. J Neurosurg 2005;102:733-7.
McIver JI, Scheithauer BW, Atkinson JLD. Deep Sylvian fissure chordoid meningioma: Case report. Neurosurgery 2005;57:e1064; discussion E1064.
Zhu HD, Chen H, Xie Q, Gong Y, Mao Y, Zhong P, et al
. Chordoid meningioma: A retrospective study of 17 cases at a single institution. Chin Med J 2013;126:789-91.
Hug EB, Devries A, Thornton AF, Munzenride JE, Pardo FS, Hedley-Whyte ET, et al
. Management of atypical and malignant meningiomas: Role of high-dose, 3D- conformal radiation therapy. J Neurooncol 2000;48:151-60.
Lo SS, Cho KH, Hall WA, Kossow RJ, Hernandez WL, McCollow KK, et al
. Single dose versus fractionated stereotactic radiotherapy for meningiomas. Can J Neurol Sci 2002;29:240-8.
Liu X, Shan B, Wang M, Xu J. World Health Organization grade II meningiomas: The role of adjuvant/salvage Gamma Knife surgery after initial surgery and prognostic factor assessment. World Neurosurg 2018;109:e352-62.
Moiyadi AV, Sridhar E, Gupta T, Ramadwar M. A primary optic nerve sheath chordoid meningioma. J Clin Neurosci 2010;17:397-9.
Nambiar A, Pillai A, Parmar C, Panikar D. Intraventricular chordoid meningioma in a child: Fever of unknown origin, clinical course, and response to treatment. J Neurosurg Pediatr 2012;10:478-81.
Yew A, Trang A, Nagasawa DT, Spasic M, Choy W, Garcia HM, et al
. Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas. J Clin Neurosci 2013;20:17-22.
Sandberg MM, Hirvonen HE, Elima KJ, Vuorio EI. Co-expression of collagens II and XI and alternative splicing of exon 2 of collagen II in several developing human tissues. Biochem J 1993;294:595-602.
Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet 2004;363:1535-43.
Jee TK, Jo KI, Seol HJ, Kong DS, Lee JI, Shin HJ. Clinical features and treatment outcome of chordoid meningiomas in a single institute. J Korean Neurosurg Soc 2014;56:194-9.
Wang XQ, Mei GH, Zhao L, Li ST, Gong Y, Zhong J, et al
. Clinical features and treatment of intracranial chordoid meningioma: A report of 30 cases. Histopathology 2013;62:1002-17.
Zhang G-J, Zhang Y-S, Zhang G-B, Yan X-J, Li C-B, Zhang L-W, et al
. Prognostic factors, survival, and treatment for intracranial World Health Organization grade II chordoid meningiomas and clear-cell meningiomas. World Neurosurgery 2018;117:e57-66.
[Figure 1], [Figure 2]